Padmanee Sharma, MD, PhD
Nivolumab (Opdivo) reduced the risk of death by 26% compared with everolimus (Afinitor) in patients with previously treated advanced renal cell carcinoma (RCC), according to 3-year follow-up data from the phase III CheckMate-025 study.
The FDA approved nivolumab in November 2015 as a treatment for patients with metastatic renal cell carcinoma following prior antiangiogenic therapy.
Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC). Bristol-Myers Squibb. http://bit.ly/2iyQKlX. Accessed November 6, 2017.
... to read the full story